Wednesday, September 9, 2009

CEO Hassan: Some Pesky "People Time" Needed -- To Walk Away With $165 Million. . . .


Was this a job-interview, yesterday? If so -- I'd rate it a low-C effort.

[If the stream below won't launch, click this to watch.]

Note also that he said "we still have a way to go" -- on getting the merger approved, here some six-months in:



Money quote, at 2 minutes, 21 seconds in:

. . . .This [selling a company] really takes a lot of time -- I've had to spend a lot of time with my people. . . .

It sure is tough, trying to defend that $165 million -- eh, Fred?

4 comments:

Anonymous said...

Let's see now

Q 1 - More mergers?

Fred - Problem is replenishing drugs going off patent with new ones.

Comment - Push through everything no matter how dangerous, take over FDA to do it, and use every possible unethical marketing trick to increase sales.

Q 2 - DTC advertising

Fred - In america we have freedom of speech.

Comment - except for Pharma employees and scientists and government employees. We wouldn't want them telling people what's really going on.

Q 3 - Merger

Fred - I need to deliver results.

Comment - get dangerous drugs like asenapine on the market and get rid of all those expensive employees.

Q 4 - Medicare going bankrupt by 2019

Fred - It's a problem.

Comment - but it's not my problem and I don't care about Medicare so long as I can sell even more drugs via Health Care Reform.

Salmon

Anonymous said...

Interesting post over on the In Vivo Blog from Sept 4th (the day the asenapine approval was announced by Merck / SP). Peter Honig (Merck Exec VP of Regulatory Affairs) is complaining about delays in FDA Drug approvals claiming a Drug Lag with Europe.

There's also a nice bit of commentary by John Jenkins from the FDA saying that to tell for sure they will need to look at the data from 2008 (when the asenapine and iloperidone approvals were held up.

Also take a look at my comments.

An FDA Reviewer

Anonymous said...

The link to the above blog posting is:

http://invivoblog.blogspot.com/2009/09/lagging-indicators-does-europe-approve.html

An FDA Reviewer

Anonymous said...

From the latest comment to the above article it looks like Fred reads SGP, the In Vivo Blog, and Pharmagossip.

Plus it seems like he's beginning to get a little testy.